Skip to main content
Premium Trial:

Request an Annual Quote

Daniel Von Hoff to Join National Cancer Advisory Board, Howard Goldstein Goes to Amnis, William Sharp new VP for Business Developmemt at Cellomics, and Others

NEW YORK, June 30 (GenomeWeb News) - Daniel Von Hoff will be appointed to President Bush's National Cancer Advisory Board for a six-year term expiring March 9, 2010, the University of Arizona news service said last week. Von Hoff is a professor at the University of Arizona in Tuscon, a clinical professor at the University of Texas at Austin, director of the cancer therapeutics program at the Arizona Health Sciences Center, and director of the translational drug development division at the Translational Genomics Institute in Phoenix.


Also, Von Hoff has also been appointed to the newly formed oncology advisory board of Synta Pharmaceuticals, the Lexington, Mass.-based company said last week.



Howard Goldstein has become senior vice president of sales and marketing, a newly created position, at Seattle-based Amnis, the company said today. Most recently, he was senior vice president for sales, service, and marketing at Argonaut Technologies. In the past, he held sales and marketing positions at Incyte Genomics, Molecular Devices, Molecular Dynamics, and Applied Biosystems. Goldstein received an MBA from Temple University, an MS in biochemistry form the University of Dayton, and a BS in biology from Bucknell University.


William Sharp has been appointed as vice president for business development at Cellomics, the Pittsburgh-based company said last week. Most recently, he was vice president of business development at Gentra Systems.


Ian Sanders has become assistant vice president for European life-science sales at Bruker Daltonics, the company said yesterday. He will also join Bruker Daltonics' global management team. Sanders has held various positions at Bruker since 2000. He holds a PhD in drug discovery technology from the University of Bath in the UK.


Kerry Flom has joined Cepheid as vice president of clinical affairs, the company said today. Most recently, he directed the clinical and regulatory submission group at Abbott Molecular Diagnostics. Prior to that, he directed the clinical affair departments at Vysis. Flom holds a PhD in biochemistry from the University of Illinois at Urbana.


Mark Molloy has become director of biomedical proteomics at the Australian Proteome Analysis Facility at Macquarie University in Sydney, Australia, APAF said this week. He returns to APAF from Pfizer in Ann Arbor, Mich., where he was a senior principal scientist. Molloy received a PhD and a BSc in biological sciences from Macquarie University.


Patricia Allen has become vice president of finance at Alnylam Pharmaceuticals, the Cambridge, Mass.-based company said last week. She was formerly director of finance and assistant secretary at Alermes. Allen holds a BS in business administration from Bryant College.


Jim Charlton has become president of Miraculins, the Winnipeg, Canada-based proteomics company said last week. He replaces Phiet Bui, who will remain CSO and a director of the company. Charlton has been a consultant to the company through Miraculins' agreement with Genesys Venture. He was recently vice president of research at Medicure. Charlton holds a PhD in chemistry from the University of Western Ontario.


Amit Kumar has joined the board of directors of Incara Pharmaceuticals, the Research Triangle Park, NC-based company said today. He is president and CEO as well as a director of CombiMatrix. Kumar received a PhD from the California Institute of Technology and a bachelor's degree in chemistry from Occidental College in Los Angeles.


Paul McKeigue has started a collaboration with DNAPrint Genomics to develop novel statistical genomics algorithms, the company said on Monday. He is a professor at University College London and at the University of Dublin.


Harald zur Hausen has joined the scientific advisory board of the German Resource Center for Genome Research, RZPD, in Berlin. Until last year, when he retired from his post, he was the scientific chairman of the German Cancer Research Center in Heidelberg.



The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.